About Seelos
Seelos Therapeutics, Inc. is a company focused on achieving the most efficient development of products that address significant unmet needs in CNS disorders and in rare diseases.
Seelos began trading on January 24, 2019 on The Nasdaq Capital Market under the ticker symbol “SEEL”. Seelos maintains its headquarters in New York, New York and is led by Chairman, Founder, and Chief Executive Officer, Raj Mehra, Ph.D.
Seelos' robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), as well as early-stage programs in Huntington's disease, Alzheimer's disease, and Parkinson's disease.
Seelos Criteria for Drug Development
- Assets must serve a large unmet medical need, orphan population or a unique approach to existing treatments
- Assets must possess extensive scientific rationale and/or existing human data
- Seelos will look for clinically ready assets or assets where minimal pre-clinical work will be needed
- The clinical development pathway should make economic sense and be appropriate for a company our size
Please review our Privacy Policy, Terms of Use, and Accessibility information located at the bottom of this page.